Sonntag, 24. Januar 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 

JOURNAL ONKOLOGIE – STUDIE

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Rekrutierend

NCT-Nummer:
NCT04246177

Studienbeginn:
Mai 2020

Letztes Update:
22.01.2021

Wirkstoff:
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo

Indikation (Clinical Trials):
Carcinoma, Carcinoma, Hepatocellular

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Merck Sharp & Dohme Corp.

Collaborator:
Eisai Inc.

Studienleiter

Medical Director
Study Director
Merck Sharp & Dohme Corp.

Kontakt

Studienlocations (3 von 133)

Alle anzeigen

Studien-Informationen

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and

pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in

participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary

hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to

placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Has a diagnosis of HCC confirmed by radiology, histology, or cytology

- Has HCC localized to the liver and not amenable to curative treatment

- Participants with Hepatitis C virus (HCV) are eligible if treatment was completed at

least 1 month prior to starting study intervention

- Participants with Hepatitis B virus (HBV) are eligible as long as their virus is well

controlled

- Has adequately controlled blood pressure with or without antihypertensive medications

- Has adequate organ function

Exclusion Criteria:

- Is currently a candidate for liver transplantation

- Has had gastric bleeding within the last 6 months

- Has ascites that is not controlled with medication

- Has significant cardiovascular impairment within 12 months of the first dose of study

intervention such as congestive heart failure

- Has a serious nonhealing wound, ulcer, or bone fracture

Studien-Rationale

Primary outcome:

1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Time Frame - Up to ~5 years):
PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR).

2. Overall Survival (OS) (Time Frame - Up to ~5 years):
OS is defined as the time from randomization to death due to any cause.

Secondary outcome:

1. PFS per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (Time Frame - Up to ~5 years):
PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to mRECIST as assessed by BICR.

2. Objective Response Rate (ORR) per mRECIST (Time Frame - Up to ~5 years):
ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of any intratumoral arterial enhancement in all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions). Responses are according to mRECIST as assessed by BICR.

3. Disease Control Rate (DCR) per mRECIST (Time Frame - Up to ~5 years):
DCR is defined as the percentage of participants who have a best overall response of CR (disappearance of any intratumoral arterial enhancement in all target lesions), PR (at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions), or stable disease (SD). Responses are according to mRECIST as assessed by BICR.

4. Duration of Response (DOR) per mRECIST (Time Frame - Up to ~5 years):
DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR (disappearance of any intratumoral arterial enhancement in all target lesions) or PR (at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions) until the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to mRECIST as assessed by BICR.

5. Time to Progression (TTP) per mRECIST (Time Frame - Up to ~5 years):
TTP is defined as the time from randomization to the first documented disease progression. Responses are according to mRECIST as assessed by BICR.

6. Percentage of Participants Who Experience At Least One Adverse Event (AE) (Time Frame - Up to ~5 years):
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience at least one AE will be reported.

7. Percentage of Participants Who Experience At Least One Serious Adverse Event (SAE) (Time Frame - Up to ~5 years):
An SAE is an AE that results in death, is life threatening, requires or prolongs a hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants who experience at least one SAE will be reported.

8. Percentage of Participants Who Experience At Least One Hepatic Event of Clinical Interest (ECI) (Time Frame - Up to ~5 years):
Percentage of participants with Hepatic ECIs not due to disease progression or TACE as assessed by the investigator will be reported.

9. Percentage of Participants Who Discontinue Study Drug Due to an AE (Time Frame - Up to ~5 years):
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug due to an AE will be reported.

10. ORR per RESCIST 1.1 (Time Frame - Up to ~5 years):
ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR.

11. DCR per RECIST 1.1 (Time Frame - Up to ~5 years):
DCR is defined as the percentage of participants who have a best overall response of CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), or SD. Responses are according to RECIST 1.1 as assessed by BICR.

12. DOR per RECIST 1.1 (Time Frame - Up to ~5 years):
DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) until the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by BICR.

13. TTP per RECIST 1.1 (Time Frame - Up to ~5 years):
TTP is defined as the time from randomization to the first documented disease progression. Responses are according to RECIST 1.1 as assessed by BICR.

Studien-Arme

  • Experimental: Lenvatinib plus Pembrolizumab plus TACE
    Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
  • Active Comparator: Oral Placebo plus IV Placebo plus TACE
    Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).

Geprüfte Regime

  • Lenvatinib (MK-7902 / E7080 / LENVIMA® / ):
    Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) via oral capsules once a day during each 21-day cycle.
  • Pembrolizumab (MK-3475 / KEYTRUDA® / ):
    Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
  • Oral Placebo:
    Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
  • IV Placebo:
    Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
  • TACE:
    Conducted as a background procedure of chemotherapeutic and embolic agent(s).

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie